Drug Detail

Information about Insm-18 (NDGA)

Generic Name
IND	Insm-18 (NDGA)
Brand Name (US)
Manufacturer	Insmed
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.